~~<i id='70EBE3C1CF'><strike id='70EBE3C1CF'><tt id='70EBE3C1CF'><pre id='70EBE3C1CF'></pre></tt></strike></i>~~

Home» explore» fashion

fashion

author：fashion 2025-10-04 08:52:17 Page View：1

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.

Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.

Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： STAT Executive Editor Rick Berke on STAT's 8th birthday
Next article： The cancer drug shortage isn’t new — and neither are the solutions

focus

Affirmative action in medical school literally saved lives

AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

FDA reorg will put new emphasis on investigations, sources say

SarahSilbiger/GettyImagesWASHINGTON—There’sabouttobeanewacronymintown.TheFoodandDrugAdministrationis

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

FDA approves Recor Medical high blood pressure device

ReCorMedical,astartupownedbyJapanesecompanyOtsukaMedicalDevices,andMedtronichaverunstudiesthatshowed